Eli Lilly and Company (NYSE:LLY) Shares Acquired by NatWest Group plc

NatWest Group plc lifted its stake in Eli Lilly and Company (NYSE:LLY) by 2.7% in the third quarter, Holdings Channel.com reports. The firm owned 14,235 shares of the company’s stock after acquiring an additional 375 shares during the quarter. Eli Lilly and Company comprises 3.7% of NatWest Group plc’s portfolio, making the stock its 10th largest holding. NatWest Group plc’s holdings in Eli Lilly and Company were worth $12,611,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Banque Cantonale Vaudoise lifted its holdings in shares of Eli Lilly and Company by 9.9% during the 1st quarter. Banque Cantonale Vaudoise now owns 26,503 shares of the company’s stock valued at $20,617,000 after buying an additional 2,383 shares during the last quarter. Conrad Siegel Investment Advisors Inc. bought a new stake in Eli Lilly and Company in the first quarter worth approximately $231,000. Wedmont Private Capital increased its stake in shares of Eli Lilly and Company by 5.6% during the 1st quarter. Wedmont Private Capital now owns 11,825 shares of the company’s stock worth $8,955,000 after purchasing an additional 627 shares during the last quarter. Grandview Asset Management LLC increased its stake in shares of Eli Lilly and Company by 42.4% during the 1st quarter. Grandview Asset Management LLC now owns 763 shares of the company’s stock worth $593,000 after purchasing an additional 227 shares during the last quarter. Finally, Lantz Financial LLC raised its holdings in shares of Eli Lilly and Company by 1.6% during the 1st quarter. Lantz Financial LLC now owns 1,220 shares of the company’s stock valued at $949,000 after purchasing an additional 19 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on LLY shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Berenberg Bank increased their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research report on Thursday. They issued an “outperform” rating and a $1,100.00 price target on the stock. Finally, Citigroup began coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $986.00.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $917.18 on Friday. The firm has a market cap of $871.69 billion, a P/E ratio of 135.08, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The firm’s 50-day simple moving average is $920.70 and its 200-day simple moving average is $856.27. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. As a group, research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.